PMID- 35651314
OWN - NLM
STAT- MEDLINE
DCOM- 20230206
LR  - 20230206
IS  - 1477-092X (Electronic)
IS  - 1078-1552 (Linking)
VI  - 29
IP  - 2
DP  - 2023 Mar
TI  - Life threatening hepatotoxicity induced by Nilotinib.
PG  - 465-468
LID - 10.1177/10781552221102588 [doi]
AB  - INTRODUCTION: Tyrosine kinase inhibitor had changed the prognosis of chronic 
      myeloid leukemia (CML) and the overall survival had reached 95%. Unfortunately, 
      adverse events (AEs) remain an obstacle to following successful treatment in CML 
      impairing the quality of life and sometimes endangering the lives of patients. To 
      this end, we show this clinical case to discuss strategies to deal with rare AEs 
      in a way to preserve the patient's life and to maintain not only a good response 
      to treatment but also confidence and compliance of the patient. CASE REPORT: We 
      report the case of a 57-year-old woman diagnosed with CML at the chronic phase 
      who developed rare life-threatening hepatotoxicity (major cytolysis and 
      prothrombin time fall) secondary to Nilotinib used as second-line treatment. This 
      complication settled despite an optimal molecular response. MANAGEMENT AND 
      OUTCOME: We discuss below the follow-up and management in our center and 
      according to the literature with more sophisticated pharmacological methods. 
      DISCUSSION: Although we used to monitor disease molecular response to treatment, 
      we need solutions and manuscripts for monitoring drug dose parameters to avoid 
      unusual dangerous effects risking the patient life. We conclude that monitoring 
      the disease as well as the treatment pharmacokinetics is mandatory to better 
      carry on CML patients.
FAU - Khelifa, Latifa
AU  - Khelifa L
AUID- ORCID: 0000-0003-4079-6384
AD  - Department of Hematology, 63745Hedi Chaker Hospital Sfax, Tunisia.
FAU - Ben Amor, Imen
AU  - Ben Amor I
AD  - Department of Hematology, 63745Hedi Chaker Hospital Sfax, Tunisia.
FAU - Kassar, Olfa
AU  - Kassar O
AD  - Department of Hematology, 63745Hedi Chaker Hospital Sfax, Tunisia.
FAU - Mdhaffer, Moez
AU  - Mdhaffer M
AD  - Department of Hematology, 63745Hedi Chaker Hospital Sfax, Tunisia.
FAU - Hdiji, Sondes
AU  - Hdiji S
AD  - Department of Hematology, 63745Hedi Chaker Hospital Sfax, Tunisia.
FAU - Elloumi, Moez
AU  - Elloumi M
AD  - Department of Hematology, 63745Hedi Chaker Hospital Sfax, Tunisia.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20220601
PL  - England
TA  - J Oncol Pharm Pract
JT  - Journal of oncology pharmacy practice : official publication of the International 
      Society of Oncology Pharmacy Practitioners
JID - 9511372
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Pyrimidines)
RN  - 0 (Protein Kinase Inhibitors)
SB  - IM
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - *Antineoplastic Agents/adverse effects
MH  - Quality of Life
MH  - Pyrimidines/adverse effects
MH  - *Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy/diagnosis
MH  - Protein Kinase Inhibitors/adverse effects
MH  - *Chemical and Drug Induced Liver Injury/etiology/drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Ehronic myeloid leukemia
OT  - Nilotinib
OT  - case report
OT  - hepatotoxicity
EDAT- 2022/06/03 06:00
MHDA- 2023/02/07 06:00
CRDT- 2022/06/02 01:42
PHST- 2022/06/03 06:00 [pubmed]
PHST- 2023/02/07 06:00 [medline]
PHST- 2022/06/02 01:42 [entrez]
AID - 10.1177/10781552221102588 [doi]
PST - ppublish
SO  - J Oncol Pharm Pract. 2023 Mar;29(2):465-468. doi: 10.1177/10781552221102588. Epub 
      2022 Jun 1.